J. Van Soest
Maastricht University Medical Centre
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Van Soest.
Radiotherapy and Oncology | 2018
Z. Shi; Leonard Wee; K. Foley; E. Spezi; P. Whybra; T. Crosby; J. Pablo de Mey; J. Van Soest; A. Dekker
Purpose: Radiation-induced lung disease (RILD), defined as dyspnea in this study, is a risk for patients receiving high-dose thoracic irradiation. [A1-4.2] This study is a TRIPOD (Transparent Reporting of A Multivariable Prediction Model for Individual Prognosis or Diagnosis) Type 4 validation of previously-published dyspnea models via secondary analysis of esophageal cancer SCOPE1 trial data. [A1-4.1] We quantify the predictive performance of these two models for predicting the maximal dyspnea grade ≥ 2 within 6 months after the end of high-dose chemo-radiotherapy for primary esophageal cancer.
Radiotherapy and Oncology | 2016
B.W.K. Schipaanboord; J. Van Soest; Djamal Boukerroui; Tim Lustberg; W. Van Elmpt; Timor Kadir; A. Dekker; Mark Gooding
ESTRO 35 2016 _____________________________________________________________________________________________________ quantitative measures such as the target registration error can be used during commissioning, such measures are not fully spatial and too user intensive in clinical practice. Therefore, we propose a fully automatic and quantitative approach to DIR quality assessment including multiple measures of numerical robustness and biological plausibility.
Medical Physics | 2015
D.I. Thwaites; Lois C Holloway; Michael Bailey; S Barakat; Martin G Carolan; G. Delaney; Matthew Field; Andre Dekker; Tim Lustberg; Andrew Alexis Miller; J. Van Soest; Shalini K Vinod; Sean Walsh
Purpose: Large amounts of routine radiotherapy (RT) data are available, which can potentially add clinical evidence to support better decisions. A developing collaborative Australian network, with a leading European partner, aims to validate, implement and extend European predictive models (PMs) for Australian practice and assess their impact on future patient decisions. Wider objectives include: developing multi-institutional rapid learning, using distributed learning approaches; and assessing and incorporating radiomics information into PMs. Methods: Two initial standalone pilots were conducted; one on NSCLC, the other on larynx, patient datasets in two different centres. Open-source rapid learning systems were installed, for data extraction and mining to collect relevant clinical parameters from the centres’ databases. The European DSSs were learned (“training cohort”) and validated against local data sets (“clinical cohort”). Further NSCLC studies are underway in three more centres to pilot a wider distributed learning network. Initial radiomics work is underway. Results: For the NSCLC pilot, 159/419 patient datasets were identified meeting the PM criteria, and hence eligible for inclusion in the curative clinical cohort (for the larynx pilot, 109/125). Some missing data were imputed using Bayesian methods. For both, the European PMs successfully predicted prognosis groups, but with some differences in practice reflected. For example, the PM-predicted good prognosis NSCLC group was differentiated from a combined medium/poor prognosis group (2YOS 69% vs. 27%, p<0.001). Stage was less discriminatory in identifying prognostic groups. In the good prognosis group two-year overall survival was 65% in curatively and 18% in palliatively treated patients. Conclusion: The technical infrastructure and basic European PMs support prognosis prediction for these Australian patient groups, showing promise for supporting future personalized treatment decisions, improved treatment quality and potential practice changes. The early indications from the distributed learning and radiomics pilots strengthen this. Improved routine patient data quality should strengthen such rapid learning systems.
Medical Physics | 2016
Devis Peressutti; B.W.K. Schipaanboord; J. Van Soest; Tim Lustberg; W. Van Elmpt; Timor Kadir; Andre Dekker; Mark Gooding
Radiotherapy and Oncology | 2018
Mark Gooding; A. Smith; Devis Peressutti; Paul Aljabar; E. Evans; S. Gwynne; C. Hammer; H.J.M. Meijer; R. Speight; C. Welgemoed; Tim Lustberg; J. Van Soest; A. Dekker; W. Van Elmpt
Radiotherapy and Oncology | 2018
W. Van Elmpt; Tim Lustberg; J. Van Soest; Mark Gooding; A. Dekker
Radiotherapy and Oncology | 2018
Tim Lustberg; J. Van der Stoep; Devis Peressutti; Paul Aljabar; W. Van Elmpt; J. Van Soest; Mark Gooding; A. Dekker
Radiotherapy and Oncology | 2018
Matthew Field; Lois C Holloway; Shalini K Vinod; Mohamed Barakat; V. Ahern; Michael Bailey; Martin G Carolan; G. Delaney; Aditya K. Ghose; E. Hau; J. Lehmann; Tim Lustberg; Andrew Alexis Miller; David Stirling; J. Sykes; J. Van Soest; Sean Walsh; A. Dekker; D.I. Thwaites
Radiotherapy and Oncology | 2018
Andrea Damiani; C. Masciocchi; N. Dinapoli; G. Chiloiro; L. Boldrini; Jacopo Lenkowicz; Maria Antonietta Gambacorta; Luca Tagliaferri; Rosa Autorino; Monica Maria Pagliara; Maria Antonietta Blasi; Roberto Gatta; R. Negro; J. Van Soest; A. Dekker; Vincenzo Valentini
Radiotherapy and Oncology | 2018
C. Masciocchi; E. Cordelli; R. Sicilia; N. Dinapoli; Andrea Damiani; Brunella Barbaro; L. Boldrini; Calogero Casà; D. Cusumano; G. Chiloiro; Maria Antonietta Gambacorta; Roberto Gatta; Jacopo Lenkowicz; J. Van Soest; A. Dekker; P. Lambin; P. Soda; G. Iannello; Vincenzo Valentini